Hand surgery & rehabilitation · 2026
Relationship between glucagon-like peptide-1 receptor agonist use and incidence of trigger finger in patients with type 2 diabetes.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Stump Kyle, Morar Henry, Talsania Alec, Centeno Dianly, Sethi Lasya, Wiekrykas Bradley
Аннотация
PURPOSE: The relationship between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use and trigger finger (TF) remains unknown. This study aims to compare rates of TF, TF release, and complications of TF release between diabetic patients with and without a history of GLP-1 RA use.
METHODS: This study utilized the TriNetX database to identify adult patients with Type II diabetes mellitus. The primary analysis included patients with and without a history of GLP-1 RA use. The secondary analysis included patients with a history of TF separated by the presence or absence of GLP-1 RA use, respectively. The tertiary analysis included patients with and without a history of GLP-1 RA use within the 6 months prior to TF release. Cohorts were propensity-matched 1:1 based on demographic characteristics and medical comorbidities. The primary outcome was the incidence of TF; the secondary outcome was the incidence of TF release. Tertiary outcomes included postoperative complications within 90 days of surgery.
RESULTS: GLP-1 RA use was associated with a significant reduction in the prevalence of trigger finger. In contrast, GLP-1 RA users demonstrated a higher prevalence of TF release and similar rates of surgical site infection, joint stiffness, wound dehiscence, and abscess irrigation and debridement following operative release.
CONCLUSIONS: Glucagon-like peptide-1 receptor agonist use in patients with type 2 diabetes mellitus is associated with a reduction in the prevalence of trigger finger without an elevation in complication risk following surgical release. Interestingly, we also observed increased prevalence of trigger finger release among glucagon-like peptide-1 receptor agonist users.
METHODS: This study utilized the TriNetX database to identify adult patients with Type II diabetes mellitus. The primary analysis included patients with and without a history of GLP-1 RA use. The secondary analysis included patients with a history of TF separated by the presence or absence of GLP-1 RA use, respectively. The tertiary analysis included patients with and without a history of GLP-1 RA use within the 6 months prior to TF release. Cohorts were propensity-matched 1:1 based on demographic characteristics and medical comorbidities. The primary outcome was the incidence of TF; the secondary outcome was the incidence of TF release. Tertiary outcomes included postoperative complications within 90 days of surgery.
RESULTS: GLP-1 RA use was associated with a significant reduction in the prevalence of trigger finger. In contrast, GLP-1 RA users demonstrated a higher prevalence of TF release and similar rates of surgical site infection, joint stiffness, wound dehiscence, and abscess irrigation and debridement following operative release.
CONCLUSIONS: Glucagon-like peptide-1 receptor agonist use in patients with type 2 diabetes mellitus is associated with a reduction in the prevalence of trigger finger without an elevation in complication risk following surgical release. Interestingly, we also observed increased prevalence of trigger finger release among glucagon-like peptide-1 receptor agonist users.